The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCICs) from the bone marrow of a patient with Gaucher disease
- PMID: 8593601
The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCICs) from the bone marrow of a patient with Gaucher disease
Abstract
Gaucher disease is a lysosomal storage disorder resulting form deficiency of the acid beta-glucosidase, glucocerebrosidase (GC). Allogeneic bone marrow transplantation has been beneficial in the treatment of Gaucher patients. Therefore, this disorder may be an ideal candidate for gene therapy by GC gene transduction of hematopoietic stem cells. We sought to increase the extent of gene transfer into CD34+ cells from the marrow of a Gaucher patient using G1GC, a simple retroviral vector containing a normal human GC cDNA. The ability of autologous stromal support and recombinant cytokines to increase the extent of transduction of colony-forming-cells (CFCs) and long-term culture initiating cells (LTCICs) was assessed. The presence of a stromal layer significantly increased the extent of GC gene transfer into 14-day CFCs, as determined by polymerase chain reaction (PCR) of individual colonies (18.8% with stroma versus 5% without, P < 0.001). Stromal support also increased the extent of transduction of LTCICs (10% with stroma versus 0.83% without, P < 0.001). Non-adherent cells from long-term bone marrow cultures initiated with CD34+ progenitors transduced on autologous stroma had higher levels of GC enzyme activity than cultures initiated with cells transduced without stroma. The percentage of cells which were GC positive by immunohistochemistry was also increased (21.1% with stroma versus 2.7% without, P = 0.0003). The addition of cytokines (IL-3, IL-6 and Steel factor) to the transduction, in the presence of stroma, significantly increased the extent of gene transfer into CFCs but not LTCICs. These studies indicate that the GC gene can be effectively transduced into LTCICs by retroviral vectors in the presence of stroma at levels significant for clinical gene therapy trials in patients with Gaucher disease.
Similar articles
-
Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol.Exp Hematol. 1994 Feb;22(2):223-30. Exp Hematol. 1994. PMID: 8299741
-
Cytokine mobilization of peripheral blood stem cells in patients with Gaucher disease with a view to gene therapy.Exp Hematol. 1995 Dec;23(14):1633-41. Exp Hematol. 1995. PMID: 8542958 Clinical Trial.
-
Transduction of mobilized peripheral blood CD34+ cells with the glucocerebrosidase cDNA.Gene Ther. 1994 May;1(3):201-7. Gene Ther. 1994. PMID: 7584082
-
[Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].J Soc Biol. 2002;196(2):175-81. J Soc Biol. 2002. PMID: 12360746 Review. French.
-
[Gene therapy for Gaucher disease].Nihon Rinsho. 1995 Dec;53(12):3089-94. Nihon Rinsho. 1995. PMID: 8577064 Review. Japanese.
Cited by
-
Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.J Inherit Metab Dis. 1997 Jun;20(2):247-57. doi: 10.1023/a:1005365008147. J Inherit Metab Dis. 1997. PMID: 9211197
-
Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors.Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12075-9. doi: 10.1073/pnas.92.26.12075. Proc Natl Acad Sci U S A. 1995. PMID: 8618847 Free PMC article.
-
Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.J Virol. 1996 Jul;70(7):4352-60. doi: 10.1128/JVI.70.7.4352-4360.1996. J Virol. 1996. PMID: 8676458 Free PMC article.
-
Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.Semin Hematol. 2013 Apr;50(2):101-30. doi: 10.1053/j.seminhematol.2013.03.025. Semin Hematol. 2013. PMID: 24014892 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous